Merozoite surface proteins in red blood cell invasion, immunity and vaccines against malaria
Malaria accounts for an enormous burden of disease globally, with Plasmodium falciparum
accounting for the majority of malaria, and P. vivax being a second important cause …
accounting for the majority of malaria, and P. vivax being a second important cause …
Malaria prevention: from immunological concepts to effective vaccines and protective antibodies
IA Cockburn, RA Seder - Nature immunology, 2018 - nature.com
Abstract Development of a malaria vaccine remains a critical priority to decrease clinical
disease and mortality and facilitate eradication. Accordingly, RTS, S, a protein-subunit …
disease and mortality and facilitate eradication. Accordingly, RTS, S, a protein-subunit …
Malaria vaccines: progress to date
DI Stanisic, MF Good - BioDrugs, 2023 - Springer
Malaria is a mosquito-borne disease caused by protozoan parasites of the genus
Plasmodium. Despite significant declines in malaria-attributable morbidity and mortality over …
Plasmodium. Despite significant declines in malaria-attributable morbidity and mortality over …
Malaria vaccines: the 60-year journey of hope and final success—lessons learned and future prospects
AA El-Moamly, MA El-Sweify - Tropical Medicine and Health, 2023 - Springer
Background The world has made great strides towards beating malaria, although about half
of the world population is still exposed to the risk of contracting malaria. Developing an …
of the world population is still exposed to the risk of contracting malaria. Developing an …
Malaria vaccines: from the past towards the mRNA vaccine era
ME Tsoumani, C Voyiatzaki, A Efstathiou - Vaccines, 2023 - mdpi.com
Plasmodium spp. is the etiological agent of malaria, a life-threatening parasitic disease
transmitted by infected mosquitoes. Malaria remains a major global health challenge …
transmitted by infected mosquitoes. Malaria remains a major global health challenge …
Comprehensive review on various strategies for antimalarial drug discovery
M Mishra, VK Mishra, V Kashaw, AK Iyer… - European journal of …, 2017 - Elsevier
The resistance of malaria parasites to existing drugs carries on growing and progressively
limiting our ability to manage this severe disease and finally lead to a massive global health …
limiting our ability to manage this severe disease and finally lead to a massive global health …
[HTML][HTML] Recent advances in recombinant protein-based malaria vaccines
SJ Draper, E Angov, T Horii, LH Miller, P Srinivasan… - Vaccine, 2015 - Elsevier
Plasmodium parasites are the causative agent of human malaria, and the development of a
highly effective vaccine against infection, disease and transmission remains a key priority. It …
highly effective vaccine against infection, disease and transmission remains a key priority. It …
The path of malaria vaccine development: challenges and perspectives
C Arama, M Troye‐Blomberg - Journal of internal medicine, 2014 - Wiley Online Library
Malaria is a life‐threatening disease caused by parasites of the P lasmodium genus. In
many parts of the world, the parasites have developed resistance to a number of antimalarial …
many parts of the world, the parasites have developed resistance to a number of antimalarial …
Controlled human malaria infection of healthy adults with lifelong malaria exposure to assess safety, immunogenicity, and efficacy of the asexual blood stage malaria …
JC Dejon-Agobe, U Ateba-Ngoa… - Clinical Infectious …, 2019 - academic.oup.com
Background GMZ2 is a recombinant malaria vaccine inducing immune responses against
Plasmodium falciparum (Pf) merozoite surface protein-3 and glutamate-rich protein. We …
Plasmodium falciparum (Pf) merozoite surface protein-3 and glutamate-rich protein. We …
Progress and prospects for blood-stage malaria vaccines
K Miura - Expert review of vaccines, 2016 - Taylor & Francis
There have been significant decreases in malaria mortality and morbidity in the last 10-15
years, and the most advanced pre-erythrocytic malaria vaccine, RTS, S, received a positive …
years, and the most advanced pre-erythrocytic malaria vaccine, RTS, S, received a positive …